Diagnosis of latent Mycobacterium tuberculosis infection: tuberculin test versus interferon-gamma release

Ferreira, Thaís Furtado; Matsuoka, Pollyanna da Fonseca Silva; Santos, Alcione Miranda dos; Caldas, Arlene de Jesus Mendes

doi:10.1590/0037-8682-0258-2015

Cited by 8 publications

(9 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In recent years, the studies of QFT-GIT performance have become more documented in non-developed countries such as Iran, India, Zambia, Brazil, etc. 5 , 6 . Currently available data suggest that the QFT-GIT test is less influenced by prior BCG vaccination and environmental mycobacteria 7 .…”

Section: Introductionmentioning

confidence: 99%

QuantiFERON-TB Gold In-Tube test in active tuberculosis patients and healthy adults

Phetsuksiri

Srisungngam

Rudeeaneksin

et al. 2018

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

Interferon-gamma (IFN-γ) release assays have improved latent tuberculosis (TB) detection and have been considered promising for the diagnosis of TB disease. However, diagnosis efficacy data is limited in high burden countries. The aim of this study was to determine the diagnostic potential of the QuantiFERON-TB Gold In-Tube (QFT-GIT) test for the diagnosis of active TB in an endemic setting for TB. A cross-sectional study was conducted in a group of 102 Thai patients with clinical symptoms and chest x-ray findings suggesting of active pulmonary TB and a group of 112 healthy adults. Testing was carried out using sputum microscopy, mycobacterial culture and QFT-GIT test. Of these patients, QFT-GIT was positive in 73 (71.57%), negative in 27 (26.47%), and undetermined in 2 (1.96%) cases. Among healthy controls, QFT-GIT was positive in 18 (16.07%), negative in 93 (83.04%), and undetermined in 1 (0.89%) person. Based on TB culture results, the sensitivity of QFTGIT for diagnosing active TB was 84.21% (95% confidence interval (CI); 72.13-92.52). The positive and negative predictive values were 65.75% (95% CI; 59.26-71.70) and 66.67% (95% CI; 49.94-80.04), respectively. The median IFN-γ level in culture-confirmed TB patients was 3.91 compared to 0.03 IU/mL of the healthy group. QFT-GIT appears to be a useful indirect test for TB diagnosis in Thailand and its use is recommended in association with clinical and radiological assessments for identifying active or latent TB.

show abstract

Section: Introductionmentioning

confidence: 99%

QuantiFERON-TB Gold In-Tube test in active tuberculosis patients and healthy adults

Phetsuksiri

Srisungngam

Rudeeaneksin

et al. 2018

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

show abstract

“…However, they may have a positive TST reaction or a positive TB blood test, and may develop active TB if they suffer an immune system deficiency. 1 , 4 , 5 , 16 – 20…”

Section: Discussionmentioning

confidence: 99%

“…Ferreira and colleagues maintain that treatment of individuals with TB disease and the identification and treatment of LTBI contacts are the two most important strategies for the control of TB. 16 However, there is no gold standard test for diagnosis of LTBI. TST and blood (interferon-gamma release assay) tests are performed to diagnose LTBI.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Use of biologic agents and risk of tuberculosis in Brazil, a tuberculosis high-burden country

Chaer¹,

Valim²,

Reis³

et al. 2020

DIC

View full text Add to dashboard Cite

Background Brazil is a country with a high burden of tuberculosis (TB). The immunomodulatory effect of biological therapies is associated with an increased risk of infection. This study evaluated the frequency of TB infection in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), juvenile idiopathic arthritis (JIA), and psoriatic arthritis (PsA) after the use of biologic agents in a single center of rheumatology. Methods In this observational study, 161 consecutive adult patients with RA, JIA, AS, and PsA using biological therapy were followed up during 55 months to evaluate the occurrence of TB infection throughout treatment. All patients were screened for latent TB infection (LTBI), and TB disease was excluded before introduction of biological therapy. Patients with LTBI received prophylaxis with isoniazid before the start of biological treatment. Results Of 161 patients on biologics, 31 (19.25%) had positive tuberculin skin test (TST) and received LTBI treatment. Eleven (6.8%) cases of TB were detected in patients on biologics, six (54.5%) had AS, one had PsA (9.09%), two had RA (18.18%), and two had JIA (18.18%). Regarding the use of different biologics, six (54.5%) patients received adalimumab, three (27.2%) infliximab, one (9.09%) etanercept, and one (9.09%) tocilizumab. Conclusion In this study, the frequency of TB infection among 161 patients on biologics, during 55 months of follow-up, was 6.8%. Compared with the national registry of patients receiving biologics (BiobadaBrasil — January 01, 2009 to May 31, 2013), a higher incidence of TB (6.8 versus 0.44%) was found in this sample of patients receiving biological therapy. This study highlights that in a country with high TB burden, the possibility of TB infection in a patient receiving biological therapy should always be considered, even after prophylaxis with isoniazid.

show abstract

“…291,292 Further, TST may generate false negatives in hosts who are pregnant, or immunosuppresses due to malignancy, nutrition, HIV/AIDS, or those receiving immune modulating therapy given the reliance of the TST on the ability of the immune system to generate a response. 293,294,295 Another important screening tool for latent disease are IFN-gamma release assays (IGRAs). Currently, two blood assay tests are commercially available: Quanti-FERON-TB Gold In-Tube (QFT-GIT;…”

Section: Department Of State Appoints the Physicians Who Perform The mentioning

confidence: 99%

Cost of care for hospitalized patients with pulmonary mycobacterial diseases in the United States.

Allen¹

View full text Add to dashboard Cite

Diagnosis of latent Mycobacterium tuberculosis infection: tuberculin test versus interferon-gamma release

Cited by 8 publications

References 19 publications

QuantiFERON-TB Gold In-Tube test in active tuberculosis patients and healthy adults

QuantiFERON-TB Gold In-Tube test in active tuberculosis patients and healthy adults

Use of biologic agents and risk of tuberculosis in Brazil, a tuberculosis high-burden country

Cost of care for hospitalized patients with pulmonary mycobacterial diseases in the United States.

Contact Info

Product

Resources

About